redhillbio.com - RDHL Forward P/S Multiple

Brandmark of redhillbio.com (RDHL)

Liquidity shortages and drug promotion costs are weighing on the budget of RedHill Biopharma (RDHL), which is why the company's forward P/S valuation, where GURU.Markets data informs this chart, has a current value of 0.30. Unique FDA-approved formulas provide stability, while growth prospects are based on the development of targeted antibiotics for the hospital sector and the treatment of gastrointestinal infections.

RedHill Biopharma Ltd - RDHL Market Cap to Expected Sales Ratio (period 07/04/2022 - 09/30/2024)

RedHill (RDHL) - metric breakdowns and financial figures

- current price and projected stock value:
Summary company analysis:redhillbio.com RDHL
Original product of RedHill Biopharma Ltd

The forward P/S ratio determines the market value of RedHill Biopharma (RDHL) relative to its projected annual revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the dynamics of the forward price-to-sales valuation, an investor can correlate market sales expectations for Talicia and Movantik with the success of clinical trials for oncology assets, which determines the fundamental stability of RedHill Biopharma (RDHL) within the biopharmaceutical sector.